enGene Therapeutics Inc. logo

enGene Therapeutics Inc.(ENGN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 5 days
PROFIT SINCE LAST BUY
-21.58% ▼
LAST CLOSE
$1.74
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ENGN

11/20/2026: ENGN (1-star) is a SELL. SELL for 5 days. Simulated Profits (-21.58%). Updated daily EoD!

enGene Therapeutics Inc. is a clinical-stage biotechnology company developing non-viral genetic medicines using its proprietary DDX delivery platform, primarily focusing on bladder cancer treatments. The company's main strength lies in its lead candidate, detalimogene voraplasmid, which exhibits promising clinical response rates and a convenient administration profile for community urology practices. Its primary growth story centers on successfully completing pivotal trials and commercializing treatments for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Key risks include pre-commercial revenue status, ongoing cash burn, execution uncertainties, and intense competition in oncology. The stock suits growth-oriented investors willing to accept high volatility, with key developments hinging on upcoming clinical readouts and regulatory progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-growth upside potential driven by clinical trial milestones for its lead non-viral gene therapy platform.
Momentum investorStrong fit while signal remains positiveStock price volatility and speculative momentum respond sharply to clinical readouts and regulatory announcements.
Value investorWeak fitThe lack of commercial revenue and ongoing operational losses make traditional value metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund clinical research.
Low-risk investorWeak fitHigh clinical development risks and share price volatility present a challenging profile for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price fluctuations based on trial updates and market sentiment.
Valuation riskMedium / highValuations are driven by clinical pipeline potential rather than established earnings or sales multiples.
Competition risk (clinical-stage biotechnology competition)HighNumerous competitors are racing to develop alternative treatments for non-muscle invasive bladder cancer.
Business qualityMediumThe proprietary DDX delivery platform provides scientific merit, but the business remains pre-revenue.
Dividend incomeLow / noneNo dividend is paid or expected in the near term.
Execution riskHighSuccess heavily depends on successfully completing clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 116.61M USD
Price to earnings Ratio -
1Y Target Price 4.29
Price to earnings Ratio -
1Y Target Price 4.29
Volume (30-day avg) 1.5M shares
Beta -0.24
52 Weeks Range 1.40 - 12.25
Updated Date 11/21/2026
52 Weeks Range 1.40 - 12.25
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.07

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
60.2%
Active BUY / eligible
62 / 103
30-Day BUY Count Change
+18
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
46.2%
Active BUY / eligible
18 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -14.88%
Avg. Invested days 29
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ENGN receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ENGN has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-112.7%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ENGN's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ENGN's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-112.7%, negative) and free-cash-flow growth (-104.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 78.3% (strong) and 49.5% of outstanding shares are publicly tradable (moderate). Insider ownership is only 0.11%, which materially reduces the ownership score.

Top 5 Institutional Investors

BML Capital Management LLC 9.95%
Siren, L.L.C. 9.34%
Perceptive Advisors LLC 7.20%
Ameriprise Financial Inc 3.99%
Nextech Invest, Ltd. 3.47%

Unit Economics (Per $1K Revenue)

★★★★★
ENGN generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ENGN has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Development and CollaborationsFuture commercial sales of genetic medicines and potential upfront or milestone payments from collaborative licensing partnerships.The company currently generates no product revenue and relies on capital markets and partnerships to fund operations until commercialization.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -113.76M
Price to Sales(TTM) -
Enterprise Value -113.76M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -6.01
Shares Outstanding 67.02M
Shares Floating 33.14M
Shares Outstanding 67.02M
Shares Floating 33.14M
Percent Insiders 0.11
Percent Institutions 78.33

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.